What is the clinical question related to the use of RAS inhibition in patients with CKD?
The clinical question related to the use of RAS inhibition in patients with CKD is: In patients with CKD, does RAS inhibition compared to placebo/no treatment or standard of care improve clinical efficacy outcomes and reduce adverse effects?